TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Walking Away From Type 2 Diabetes: a Cluster Randomized Controlled Trial to Investigate the Effect of Structured Education on Walking Activity in Those With a High Risk of Developing Type 2 Diabetes
Brief Summary: Diabetes is a debilitating chronic disease reaching epidemic proportions. Lack of physical activity is a key factor driving this epidemic and it is therefore vital that workable methods of encouraging people to exercise and reducing inactivity are developed and tested if we are to stem the rising tide of diabetes.

This cluster randomised controlled trial will investigate whether a person-centred group educational programme can increase walking activity and reduce the risk of developing diabetes in high-risk individuals identified in primary care settings. In total 804 patients will be recruited to the study. Physical activity levels, glucose control, incidence of type 2 diabetes and anthropometric measurements (e.g. weight) will be tested on an annual basis over three years.

This trial will be the first to test the feasibility, efficacy and value for money of a physical activity intervention aimed at reducing the risk of diabetes in a community setting in a multi-ethnic population in the UK.

Primary research hypothesis: A pragmatic structured education programme aimed at promoting walking activity initiates long-term increases in physical activity in individuals identified through a risk score as having an increased risk of developing type 2 diabetes.


Options:
A: Arm Label: Lifestyle coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Watchers | Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight Watchers, Behavioral: National Diabetes Education Program | Intervention Type: BEHAVIORAL; Name: Weight Watchers; Assigned to Arm(s): Lifestyle coaching, Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: National Diabetes Education Program; Assigned to Arm(s): Lifestyle counseling
B: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Structured Education | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written Information | Intervention Type: BEHAVIORAL; Name: Structured Education; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Written Information; Assigned to Arm(s): Control
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE with pedometer | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PREPARE | Intervention Type: BEHAVIORAL; Name: PREPARE with pedometer; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: PREPARE; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: diet- and exercise intervention; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Exercise Training in Combination With Dopamine Agonist to Physical Fitness Parameters and Quality of Life in Dialysis Patients With the Restless Legs Syndrome.
Brief Summary: Uremic etiology Restless legs syndrome (RLS) has been associated with poorer quality of life (QoL) compared to RLS-free counterparts mainly due to sleep deprivation factors. Exercise training in hemodialysis (HD) patients with RLS has been proven to be a safe approach in temporally ameliorating RLS symptoms similarly to the use of pharmacological treatment with dopamine agonists. However it not known whether the exercise anabolic stimulus and the dopamine agonist treatment could act synergistically for the improvement of physical functioning and muscle performance as well as in the amelioration of augmentation symptoms in hemodialysis patients with RLS.


Options:
A: Arm Label: Dopamine Agonist Group; Type: EXPERIMENTAL; Interventions: Other: Dopamine Agonist and Exercise | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Dopamine Agonist and Exercise | Intervention Type: OTHER; Name: Dopamine Agonist and Exercise; Assigned to Arm(s): Dopamine Agonist Group, Placebo Group
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: XP13512 (GSK1838262); Type: EXPERIMENTAL; Interventions: Drug: XP13512 (GSK1838262) | Intervention Type: DRUG; Name: XP13512 (GSK1838262); Assigned to Arm(s): XP13512 (GSK1838262) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: XP13512 600MG; Type: EXPERIMENTAL; Interventions: Drug: XP13512 600MG | Arm Label: XP13512 1200MG; Type: EXPERIMENTAL; Interventions: Drug: XP13512 1200MG | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: PLACEBO | Intervention Type: DRUG; Name: XP13512 600MG; Assigned to Arm(s): XP13512 600MG | Intervention Type: DRUG; Name: XP13512 1200MG; Assigned to Arm(s): XP13512 1200MG | Intervention Type: DRUG; Name: PLACEBO; Assigned to Arm(s): Placebo
D: Arm Label: GEn (XP13512/GSK1838262) 600 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: GEn (XP13512/GSK1838262) 1200 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: GEn (XP13512/GSK1838262) 1800 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: GEn (XP13512/GSK1838262) 2400 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GEn (XP13512/GSK1838262); Assigned to Arm(s): GEn (XP13512/GSK1838262) 1200 mg, GEn (XP13512/GSK1838262) 1800 mg, GEn (XP13512/GSK1838262) 2400 mg, GEn (XP13512/GSK1838262) 600 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Exercise Training in Combination With Dopamine Agonist to Physical Fitness Parameters and Quality of Life in Dialysis Patients With the Restless Legs Syndrome.
Brief Summary: Uremic etiology Restless legs syndrome (RLS) has been associated with poorer quality of life (QoL) compared to RLS-free counterparts mainly due to sleep deprivation factors. Exercise training in hemodialysis (HD) patients with RLS has been proven to be a safe approach in temporally ameliorating RLS symptoms similarly to the use of pharmacological treatment with dopamine agonists. However it not known whether the exercise anabolic stimulus and the dopamine agonist treatment could act synergistically for the improvement of physical functioning and muscle performance as well as in the amelioration of augmentation symptoms in hemodialysis patients with RLS.


Options:
A: Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): N/A
B: Arm Label: Auricular acupressure therapy; Type: EXPERIMENTAL; Interventions: Other: auricular acupressure therapy | Arm Label: sham auricular acupressure therapy; Type: SHAM_COMPARATOR; Interventions: Other: sham auricular acupressure therapy | Intervention Type: OTHER; Name: auricular acupressure therapy; Assigned to Arm(s): Auricular acupressure therapy | Intervention Type: OTHER; Name: sham auricular acupressure therapy; Assigned to Arm(s): sham auricular acupressure therapy
C: Arm Label: Dopamine Agonist Group; Type: EXPERIMENTAL; Interventions: Other: Dopamine Agonist and Exercise | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Dopamine Agonist and Exercise | Intervention Type: OTHER; Name: Dopamine Agonist and Exercise; Assigned to Arm(s): Dopamine Agonist Group, Placebo Group
D: Arm Label: Bright Light Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Bright Light Therapy | Arm Label: Wait-list intervention; Type: OTHER; Interventions: Behavioral: Wait-list intervention | Intervention Type: BEHAVIORAL; Name: Bright Light Therapy; Assigned to Arm(s): Bright Light Therapy | Intervention Type: BEHAVIORAL; Name: Wait-list intervention; Assigned to Arm(s): Wait-list intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Exercise Training in Combination With Dopamine Agonist to Physical Fitness Parameters and Quality of Life in Dialysis Patients With the Restless Legs Syndrome.
Brief Summary: Uremic etiology Restless legs syndrome (RLS) has been associated with poorer quality of life (QoL) compared to RLS-free counterparts mainly due to sleep deprivation factors. Exercise training in hemodialysis (HD) patients with RLS has been proven to be a safe approach in temporally ameliorating RLS symptoms similarly to the use of pharmacological treatment with dopamine agonists. However it not known whether the exercise anabolic stimulus and the dopamine agonist treatment could act synergistically for the improvement of physical functioning and muscle performance as well as in the amelioration of augmentation symptoms in hemodialysis patients with RLS.


Options:
A: Arm Label: Cognitive training; Type: ACTIVE_COMPARATOR; Interventions: Other: Cognitive training | Arm Label: Exercise training; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise training | Arm Label: Combined cognitive and exercise training; Type: ACTIVE_COMPARATOR; Interventions: Other: Combined cognitive and exercise training | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cognitive training; Assigned to Arm(s): Cognitive training | Intervention Type: OTHER; Name: Exercise training; Assigned to Arm(s): Exercise training | Intervention Type: OTHER; Name: Combined cognitive and exercise training; Assigned to Arm(s): Combined cognitive and exercise training
B: Arm Label: HD-Exercise-HDF; Type: EXPERIMENTAL; Interventions: Procedure: Intra-dialytic exercise | Intervention Type: PROCEDURE; Name: Intra-dialytic exercise; Assigned to Arm(s): HD-Exercise-HDF
C: Arm Label: Dopamine Agonist Group; Type: EXPERIMENTAL; Interventions: Other: Dopamine Agonist and Exercise | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Dopamine Agonist and Exercise | Intervention Type: OTHER; Name: Dopamine Agonist and Exercise; Assigned to Arm(s): Dopamine Agonist Group, Placebo Group
D: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.05%, In Patients With Actinic Keratoses on Non-head Locations (REGION-Ib)
Brief Summary: The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEP005 (ingenol mebutate) Gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Intervention Type: DRUG; Name: PEP005 (ingenol mebutate) Gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vehicle gel; Assigned to Arm(s): 2
B: Arm Label: PEP005 (Ingenol Mebutate) gel; Type: EXPERIMENTAL; Interventions: Drug: PEP005 (Ingenol Mebutate) gel, 0.015% | Arm Label: Vehicle gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle Gel | Intervention Type: DRUG; Name: PEP005 (Ingenol Mebutate) gel, 0.015%; Assigned to Arm(s): PEP005 (Ingenol Mebutate) gel | Intervention Type: DRUG; Name: Vehicle Gel; Assigned to Arm(s): Vehicle gel
C: N/A
D: Arm Label: PEP005 (ingenol mebutate) Gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEP005 (ingenol mebutate) Gel | Arm Label: Vehicle gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Intervention Type: DRUG; Name: PEP005 (ingenol mebutate) Gel; Assigned to Arm(s): PEP005 (ingenol mebutate) Gel | Intervention Type: DRUG; Name: Vehicle gel; Assigned to Arm(s): Vehicle gel

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Brief Summary: Background:

* Alveolar soft part sarcoma is a type of cancer that develops in tissues that connect, support, or surround other organs in the body. It relies heavily on new blood vessels to grow and spread through the body. There is no effective systemic treatment for patients with alveolar soft part sarcoma.
* The drug AZD2171 (cediranib) is an experimental drug, not yet approved by the Food and Drug Administration. The drug blocks the creation of new blood vessels. The drug has had initial clinical trials, and researchers are interested in determining whether cediranib is effective in inhibiting tumor growth in individuals who have alveolar soft part sarcoma.

Objectives:

- To find out whether AZD2171 works in patients who have alveolar soft part sarcoma.

Eligibility:

- Individuals 18 years of age and older who have been diagnosed with alveolar soft part sarcoma.

Design:

* After an initial screening visit, patients will take AZD2171 by mouth once a day, every day for the duration of the study. The treatment will be given in 28-day cycles.
* Patients will keep a study diary to record the doses taken, any missed doses, and any side effects.
* Patients will have the following tests and procedures during the treatment period: clinic visit with physical examination every 2 weeks during cycles 1 and 2, then at the start of each subsequent cycle, regular blood pressure monitoring, blood and urine tests, heart function tests, imagining scans to evaluate tumor size and response to the treatment, and possible tumor biopsy.


Options:
A: Arm Label: Cediranib (AZD2171) Treatment; Type: EXPERIMENTAL; Interventions: Drug: AZD2171 | Intervention Type: DRUG; Name: AZD2171; Assigned to Arm(s): Cediranib (AZD2171) Treatment
B: Arm Label: A; Type: OTHER; Interventions: Drug: axitinib | Arm Label: B; Type: OTHER; Interventions: Drug: axitinib | Arm Label: C; Type: OTHER; Interventions: Drug: axitinib | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): C
C: Arm Label: Lenvatinib; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib | Arm Label: Lenvatinib plus Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Everolimus | Arm Label: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib, Lenvatinib plus Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus, Lenvatinib plus Everolimus
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib (Sutent) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar) | Intervention Type: DRUG; Name: Sunitinib (Sutent); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sorafenib (Nexavar); Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
Brief Summary: This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease type 1 who had reached therapeutic goals with enzyme replacement therapy (ERT).


Options:
A: Arm Label: Taliglucerase alfa 30 units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Arm Label: Taliglucerase alfa 60 units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Intervention Type: DRUG; Name: Taliglucerase alfa; Assigned to Arm(s): Taliglucerase alfa 30 units/kg, Taliglucerase alfa 60 units/kg
B: Arm Label: prGCD 30 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD) | Arm Label: prGCD 60 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD) | Intervention Type: DRUG; Name: Plant cell expressed recombinant glucocerebrosidase (prGCD); Assigned to Arm(s): prGCD 30 Units/kg | Intervention Type: DRUG; Name: Plant cell expressed recombinant glucocerebrosidase (prGCD); Assigned to Arm(s): prGCD 60 Units/kg
C: Arm Label: 30 units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Arm Label: 60 units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Intervention Type: DRUG; Name: Taliglucerase alfa; Assigned to Arm(s): 30 units/kg, 60 units/kg
D: Arm Label: Investigational; Type: EXPERIMENTAL; Interventions: Drug: Eliglustat tartrate | Arm Label: Imiglucerase; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imiglucerase | Intervention Type: DRUG; Name: Eliglustat tartrate; Assigned to Arm(s): Investigational | Intervention Type: DRUG; Name: Imiglucerase; Assigned to Arm(s): Imiglucerase

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study of Diabetes Risk Reduction Program With Overweight WIC Mothers
Brief Summary: 1) to evaluate treatment fidelity of DRRP: study design, training of interventionists, delivery and receipt of the intervention, and application of the intervention in real-life settings; 2) to identify successful strategies for participant recruitment and maintaining active participation; 3) to collect and analyze preliminary indicators of DRRP's effect on dietary intake, physical activity, stress responses, and body weight; and 4) To evaluate sample representativeness of the target audience, implementation and acceptability of DRRP, and attrition rate.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management program (SM) | Arm Label: Care Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Care management program (CM) | Intervention Type: BEHAVIORAL; Name: Self-management program (SM); Assigned to Arm(s): Self-Management Program | Intervention Type: BEHAVIORAL; Name: Care management program (CM); Assigned to Arm(s): Care Management Program
B: Arm Label: Moderate lifestyle intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Moderate Lifestyle Intervention | Arm Label: Intensive lifestyle intervention; Type: EXPERIMENTAL; Interventions: Other: Intensive lifestyle intervention | Intervention Type: OTHER; Name: Moderate Lifestyle Intervention; Assigned to Arm(s): Moderate lifestyle intervention | Intervention Type: OTHER; Name: Intensive lifestyle intervention; Assigned to Arm(s): Intensive lifestyle intervention
C: Arm Label: lifestyle intervention; Type: EXPERIMENTAL; Interventions: Other: lifestyle intervention | Intervention Type: OTHER; Name: lifestyle intervention; Assigned to Arm(s): lifestyle intervention
D: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Controlled Trial in Rural Burkina Faso to Determine the Optimal Amount of Zinc to Include in a Lipid-based Nutrient Supplement (LNS). Part of the iLiNS Study
Brief Summary: To assess zinc-related biochemical and functional responses among young Burkinabe children with a presumed high risk of zinc deficiency who receive micronutrient products containing different amounts of zinc, provided with or between meals.


Options:
A: Arm Label: LNS-Zn5; Type: EXPERIMENTAL; Interventions: Dietary Supplement: LNS-Zn5 | Arm Label: LNS-Zn10; Type: EXPERIMENTAL; Interventions: Dietary Supplement: LNS-Zn10 | Arm Label: LNS-Zn0; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: LNS-Zn0 | Arm Label: Suppl-Zn5; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Suppl-Zn5 | Arm Label: Delayed intervention group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Zn5; Assigned to Arm(s): LNS-Zn5 | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Zn10; Assigned to Arm(s): LNS-Zn10 | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Zn0; Assigned to Arm(s): LNS-Zn0 | Intervention Type: DIETARY_SUPPLEMENT; Name: Suppl-Zn5; Assigned to Arm(s): Suppl-Zn5
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Zinc and ORS | Arm Label: 2; Type: OTHER; Interventions: Drug: ORS only | Intervention Type: DRUG; Name: Zinc and ORS; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ORS only; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: ZINC; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Controlled Trial in Rural Burkina Faso to Determine the Optimal Amount of Zinc to Include in a Lipid-based Nutrient Supplement (LNS). Part of the iLiNS Study
Brief Summary: To assess zinc-related biochemical and functional responses among young Burkinabe children with a presumed high risk of zinc deficiency who receive micronutrient products containing different amounts of zinc, provided with or between meals.


Options:
A: Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): N/A
B: Arm Label: LNS-Zn5; Type: EXPERIMENTAL; Interventions: Dietary Supplement: LNS-Zn5 | Arm Label: LNS-Zn10; Type: EXPERIMENTAL; Interventions: Dietary Supplement: LNS-Zn10 | Arm Label: LNS-Zn0; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: LNS-Zn0 | Arm Label: Suppl-Zn5; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Suppl-Zn5 | Arm Label: Delayed intervention group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Zn5; Assigned to Arm(s): LNS-Zn5 | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Zn10; Assigned to Arm(s): LNS-Zn10 | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Zn0; Assigned to Arm(s): LNS-Zn0 | Intervention Type: DIETARY_SUPPLEMENT; Name: Suppl-Zn5; Assigned to Arm(s): Suppl-Zn5
C: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
D: Arm Label: micronutrient powder (MNP); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: MNP, Dietary Supplement: therapeutic placebo supplement | Arm Label: placebo powder; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: therapeutic placebo supplement, Dietary Supplement: placebo powder | Arm Label: preventive zinc supplements; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: preventive zinc supplement, Dietary Supplement: therapeutic placebo supplement | Arm Label: therapeutic zinc supplements; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: therapeutic zinc supplement, Dietary Supplement: preventive placebo supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: MNP; Assigned to Arm(s): micronutrient powder (MNP) | Intervention Type: DIETARY_SUPPLEMENT; Name: preventive zinc supplement; Assigned to Arm(s): preventive zinc supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: therapeutic zinc supplement; Assigned to Arm(s): therapeutic zinc supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: preventive placebo supplement; Assigned to Arm(s): therapeutic zinc supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: therapeutic placebo supplement; Assigned to Arm(s): micronutrient powder (MNP), placebo powder, preventive zinc supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo powder; Assigned to Arm(s): placebo powder

Answer: B